Yellow Cake's Dilution Discount: What the AGM Votes Reveal About the Uranium Play

Yellow Cake holds 24.4 million pounds of physical uranium. The shares trade at roughly a 12% discount to the value of that uranium. On the surface, it looks like buying a commodity at a discount with no debt and no operational risk.

The catch lives in how the company pays for more uranium — and what that means for the slices that existing shareholders own.

How the machine works

Yellow Cake plc (LSE: YCA) is not a uranium miner. It is a listed holding vehicle — a Jersey-based company on the London Stock Exchange's AIM market that buys uranium oxide concentrate (U3O8), stores it at Cameco and Orano facilities in Canada and France, and holds it for the long term. Shareholders get exposure to uranium price movements through the fluctuation in net asset value, or NAV. There is no dividend.

The company sources uranium through a ten-year framework agreement with Kazatomprom, the world's largest uranium producer, which lets Yellow Cake acquire up to $100 million worth of uranium annually through 2027 at fixed prices. The latest tranche — 1.16 million pounds at a fixed price of $86.15 per pound — was delivered on August 11, 2026, bringing total holdings to 24.4 million pounds.

That fixed price is the key mechanism. The uranium spot price touched $94 per pound at the end of January 2026, pulled back through spring, and was hovering around $90 per pound by August. Buying at $86.15 when spot is $90 means each Kazatomprom purchase immediately creates unrealized upside on roughly 4 cents per pound. The company is systematically buying below market — which is why the NAV per share has consistently climbed ahead of the spot price over multi-year periods.

But this machine has a fuel input: cash. And Yellow Cake raises cash by issuing new shares.

The dilution cycle

In February 2026, the company placed 12.8 million new shares at £6.29, raising approximately £80.6 million. That represented about 5.3% dilution to existing shareholders. The proceeds were committed to the $100 million Kazatomprom purchase. This is the same playbook repeated since the company went public in 2018 — raise equity, buy uranium, grow NAV per share, repeat.

Between 2023 and 2026 alone, the company has conducted multiple share placings: roughly $75 million in February 2023, £80.6 million in February 2026, plus earlier rounds in 2019 and 2022. Each one dilutes existing holders. The total share count has grown from the IPO to approximately 257 million shares today.

For existing shareholders, the question is straightforward: does NAV per share grow fast enough to compensate for the ownership being watered down? The math has tilted in favor recently. As of June 30, 2026, NAV stood at £6.34 per share. The share price was 561p the same day. The company also conducted a £10 million buyback in June-July 2026, repurchasing 1.36 million shares at an average of 544p — but only on days when the closing price was at least 10% below pro-forma NAV, a built-in value discipline.

The buyback partially offsets the dilution. But it is a drop in the ocean compared to the placings.

What the AGM vote tells you

This is where the AGM becomes useful data. At the September 2025 meeting, shareholders were asked to disapply pre-emption rights — the rule that would force the company to offer new shares first to existing holders proportionally before selling them to outside investors. Disapplying pre-emption rights gives the board flexibility to place shares quickly, which is essential for a company that needs to raise capital rapidly to execute uranium purchases.

The resolution passed with 80.2% in favor. But 22.6 million votes — 19.8% of the total — were cast against. That was the highest dissent level of any governance resolution at the meeting. For comparison, the authority to allot shares (Resolution 12) drew 15.9% opposition.

Almost a fifth of shareholders said no to the mechanism that enables continued dilution. That is not a revolt — the resolution passed comfortably. But it is a signal that the trade-off is not invisible to the investor base. The company acknowledged this, engaging with shareholders after the meeting about concerns raised around the Group's structure. By July 2025, the company had published responses addressing shareholder feedback on its capital-raising approach.

The 2026 AGM on September 8th passed all resolutions, continuing the mandate. The pattern is clear: the majority accepts dilution as the cost of growing the uranium inventory, while a meaningful minority remains uncomfortable with the structural reliance on equity issuance.

What you are actually buying

There are two ways to look at Yellow Cake depending on when you entered.

If you bought at the IPO price of £2.00 and have held through every dilution event, your returns have been substantial — the NAV per share was £6.34 as of June 2026, well above entry. The compounding effect of buying uranium below spot has outpaced the dilution drag for long holders.

If you are buying today at 580p against a NAV of roughly £6.34, you are paying a discount but entering a company whose next $100 million in purchases will require another equity raise. Your slice of the NAV will be diluted by whoever subscribes next. The value creation from buying below spot has to clear that hurdle before your per-share NAV improves.

This is fundamentally different from buying a uranium miner, which generates operating cash flow and can reinvest from earnings. It is also different from a pure-play ETF or trust. The Sprott Physical Uranium Trust (traded as U.UN on the TSX) holds 81.4 million pounds of U3O8 — more than three times Yellow Cake's inventory — with a management fee of 0.68% but no dilution from growth financings. Sprott's model is static: it holds and the NAV tracks spot minus fees. Yellow Cake is active: it buys at negotiated prices and grows the pile, but at the cost of repeated capital calls on shareholders.

The investment case

The case for Yellow Cake rests on three pillars that need to hold simultaneously:

Uranium supply constraints sustain prices above Yellow Cake's average acquisition cost. The company's Kazatomprom framework fixes purchases at around $86 per pound. If spot uranium collapses toward $60 — plausible if demand growth stalls or a supply surge materializes — the buy-below-market advantage evaporates and the portfolio carries unrealized losses. The company's own annual report identifies dilution and option pricing risks explicitly.

The NAV growth per share continues to outpace the dilution rate. This is a rolling test. Each new placing dilutes existing holders by roughly 5%, but if the acquired uranium appreciates above its purchase price and the share price moves toward NAV, the NAV per share can still climb. Q1 2026 showed NAV per share rising 5% in a quarter where the portfolio grew 9.7% — suggesting the dilution was more than absorbed. But it is not guaranteed going forward.

The market discount to NAV persists or widens. At roughly 12% below NAV as of early September, the shares offer a margin of safety. But AIM-listed companies like Yellow Cake trade at discounts precisely because of liquidity risk and dilution risk. If the discount narrows to zero or turns positive, the upside from the NAV gap closes.

The debt-free balance sheet with $150 million in net current assets provides breathing room. The company is not in financial distress. The $419 million profit after tax for the year to March 2026 was driven by a $434 million fair-value gain as spot rose 30% — so the "earnings" are essentially paper gains on the uranium, not operating income. That is worth understanding before latching onto the P/E ratio.

Yellow Cake is a leveraged bet on uranium through the structure of its Kazatomprom deal, not through debt. The leverage comes from systematically adding inventory at below-market prices while share count grows. For investors who accept dilution as the entry fee, the company offers something no uranium miner or ETF replicates: a listed vehicle that actively accumulates physical supply at negotiated prices. For investors who do not, the AGM dissent votes are the clearest sign that this is not a universally comfortable model.

The factor question is not whether uranium will rise — it is whether Yellow Cake's per-share NAV creation is durable enough to clear the dilution hurdle on every cycle. So far it has. That is the evidence, not the forecast.